Regenerative medicine holds the potential to revolutionize healthcare, but critical work needs to be done now to ensure these new therapies will be safe, effective, affordable, and widely available to patients who need them.
That is one of the key conclusions of a paper published last week in
Cell & Gene Therapy Insights that outlines the recommendations of an international workshop hosted by
Medicine by Design at the University of Toronto (U of T), in collaboration with
CCRM, the
Toronto Health Economics and Technology Assessment Collaborative (THETA) at UHN, and
Loughborough University in the U.K.
“As more regenerative medicine therapies move closer to the clinic, now is the time to engage policy makers, governments, healthcare providers and other stakeholders in these important conversations,” says Dr.Murray Krahn, the paper’s corresponding author and director of THETA.
Read more about the paper.
“Laying this groundwork early will ensure our healthcare system can adopt and implement regenerative medicine therapies efficiently and effectively, and in ways that align with the social values of Canadians,” adds Dr. Krahn, who is also an attending physician at UHN, Senior Scientist at the Toronto General Hospital Research Institute and a professor at the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine at U of T.
Funded by a $114-million grant from the federal government's
Canada First Research Excellence Fund, Medicine by Design brings together more than 130 researchers from across U of T and its affiliated hospitals to advance regenerative medicine discoveries and accelerate them toward impact.
